Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of 200 mg Casodex in Advanced Prostate Cancer
NCT00846976Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 1994
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bicalutamide in prostate cancer (PCa), sponsored by AstraZeneca. Primary endpoint: Safety profile of patients treated with a 200 mg daily dose of CASODEX. Started Dec 1994; status: completed.
02
Drugs
bicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00846976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846976.